ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CRDL Cardiol Therapeutics Inc

2.4301
0.0701 (2.97%)
Last Updated: 11:03:19
Delayed by 15 minutes

Period:

Draw Mode:

Volume 448,096
Bid Price 2.43
Ask Price 2.44
News -
Day High 2.59

Low
0.661

52 Week Range

High
3.12

Day Low 2.41
Share Name Share Symbol Market Stock Type
Cardiol Therapeutics Inc CRDL NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0701 2.97% 2.4301 11:03:19
Open Price Low Price High Price Close Price Previous Close
2.56 2.41 2.59 2.36
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,010 448,096 US$ 2.49 US$ 1,117,642 - 0.661 - 3.12
Last Trade Type Quantity Price Currency
11:03:19 500 US$ 2.4301 USD

Cardiol Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
218.78M 65.11M - 0 -28.13M -0.43 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cardiol Therapeutics News

Date Time Source News Article
6/13/202406:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/28/202410:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/14/202416:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/14/202406:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/26/202409:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/21/202406:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/15/202412:15AllPennyStocks.comOrphan Drug Designation Sends Shares of this Dual-Listed..
2/15/202406:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/24/202406:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/09/202406:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/05/202306:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/16/202305:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CRDL Message Board. Create One! See More Posts on CRDL Message Board See More Message Board Posts

Historical CRDL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.533.122.312.661,499,962-0.0999-3.95%
1 Month2.403.122.122.57728,2540.03011.25%
3 Months1.553.121.432.27462,2350.880156.78%
6 Months0.923.120.79121.88393,8171.51164.14%
1 Year0.763.120.6611.56298,3581.67219.75%
3 Years2.634.960.452.06318,904-0.1999-7.60%
5 Years2.634.960.452.06318,904-0.1999-7.60%

Cardiol Therapeutics Description

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Your Recent History

Delayed Upgrade Clock